Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

News Daily News

DAPT De-escalation Success Varies by Sex: Meta-analysis

Yael L. Maxwell

August 21, 2025

News Daily News

‘Smart’ Approach Wins for Post-PCI Antiplatelet Prescribing

Yael L. Maxwell

April 19, 2021

News Daily News

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Caitlin E. Cox

June 13, 2019

News Daily News

Majority of SCAD Lesions Heal With Conservative Treatment

Michael O'Riordan

February 27, 2019

News Conference News ACC 2018

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Yael L. Maxwell

March 19, 2018

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Presenter: Michael S. Lee, Dirk Sibbing, John A. Bittl

October 30, 2017

Presentation TCT 2017

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Presenter: Michael S. Lee, Dirk Sibbing, David Erlinge

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

Presentation TCT 2017

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Uwe Zeymer

October 30, 2017

Presentation TCT 2017

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Eric R. Bates

October 30, 2017

$Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!$

Presentation TCT 2017

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, A. Michael Lincoff

October 30, 2017

Presentation TCT 2017

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

Presenter: Michael S. Lee, Dirk Sibbing, Francesco Franchi

October 30, 2017

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Todd Neale

September 07, 2017

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

Presentation TCT 2014

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

Presenter: Dirk Sibbing

September 14, 2014

Presentation TCT 2014

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Dirk Sibbing

September 14, 2014

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

News Daily News

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Caitlin E. Cox

June 07, 2012

Advertisement

DAPT De-escalation Success Varies by Sex: Meta-analysis

‘Smart’ Approach Wins for Post-PCI Antiplatelet Prescribing

Platelet Function and Genetic Testing to Guide P2Y12 Inhibitor Meds in PCI: Updated Consensus

Majority of SCAD Lesions Heal With Conservative Treatment

Loading Dose Smooths Switch From Ticagrelor to Clopidogrel After PCI: SWAP-4

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Should Choice of Parenteral Therapy for Primary PCI in STEMI Depend on Vascular Access?

Parenteral Therapy in STEMI: Does VALIDATE Change the Equation?

Why I Use Cangrelor for Primary PCI in STEMI!

Why I Prefer Bivalirudin for Primary PCI in STEMI!

Why I Prefer a Heparin Plus a GPI for Primary PCI in STEMI!

Why I Prefer Unfractionated Heparin Without GPI for Primary PCI in STEMI!

STEMI Case Presentation: Why the Choice of Patental Therapy Matters

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

No: Vorapaxar Is Effective, but Prasugrel and Ticagrelor are Preferred!

De-escalating Antiplatelet Treatment in ACS Patients: New Concepts and Upcoming Studies

Presentations Examine Multiple Facets of Antiplatelet Agents

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

La Opción Antitrombótica durante una PCI Influye en los Resultados de los Malos Respondedores al Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content